SF1126
| Code | Size | Price |
|---|
| TAR-T16875-5mg | 5mg | £724.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
SF1126 is a relevant pan and dual first-in-class PI3K/BRD4 inhibitor. SF1126 is an RGDS-conjugated LY294002 prodrug, which is designed to exhibit increased solubility and bind to specific integrins within the tumor compartment.
CAS:
936487-67-1
Formula:
C39H48N8O14
Molecular Weight:
852.855
Purity:
0.98
SMILES:
NC(=N)NCCC[C@H](NC(=O)CCC(=O)OC[N+]1(CCOCC1)c1cc(=O)c2cccc(-c3ccccc3)c2o1)C(=O)NCC(=O)N[C@@H](CC([O-])=O)C(=O)N[C@@H](CO)C(O)=O
References
1. Garlich JR, et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008 Jan 1;68(1):206-15.